Chlorpyrifos pharmaceutical-grade active is not listed in USP-NF, Ph. Eur., or BP as a human drug substance. No human-approved oral or injectable chlorpyrifos product is registered in the United States or European Union. The downstream formulation routes described here are confined to veterinary ectoparasiticide dosage forms in jurisdictions where national registration applies. The crystalline material exhibits a melting point of 41–42 °C, water solubility of 1.4 mg/L at 25 °C, and rapid hydrolysis above pH 7.0. These properties govern every unit operation from dry granulation to aseptic filtration.

Direct compression of chlorpyrifos pharma grade is performed at room conditions not exceeding 35% RH and 25 °C. The API is milled through a 0.5 mm sieve until D90 is below 150 µm for blend uniformity. Rotary tablet press tooling is cooled to 15–20 °C because local die-wall friction can raise surface temperature toward the 41–42 °C melting point. At 100 kg batch scale, the cooled feed frame maintains die wall temperature below 25 °C during a 45 min compression run. A representative compressed core contains 8% w/w API, 60% microcrystalline cellulose, 28% anhydrous lactose, 3% crospovidone, 0.8% colloidal silicon dioxide, and 0.2% magnesium stearate. The lubricant is added last in a V-blender at 20 rpm for 15 min to avoid shear-induced amorphous conversion of magnesium stearate. Compression force is set at 10–15 kN with ejection force below 1.2 kN to minimize frictional heat. Tablet hardness is controlled at 6–8 kP using a screw-feed rotary press with cooled die table. Disintegration is measured per USP <701> in 900 mL water at 37 °C; the limit is not more than 15 min. Dissolution uses USP <711> apparatus 2 at 50 rpm in 900 mL of 0.1 M hydrochloric acid containing 0.5% polysorbate 80. The in-house specification limits Q to 80% at 45 min because free drug aqueous solubility is only 1.4 mg/L. Uniformity of dosage units is assessed by USP <905>; acceptance value is not more than 15.0. Residual solvent for any pre-compression granulation solvent is verified by ICH Q3C(R8). The finished 25 mg and 50 mg veterinary oral tablets are not intended for human use or for food-producing animals because chlorpyrifos residues in edible tissues are strictly controlled under national veterinary residue regulations.

What Moisture Threshold Prevents Hard Gelatin Capsule Cross-Linking and Chlorpyrifos Hydrolysis?

In hard gelatin capsule dry-fill operations, the environmental RH is held below 30% and the fill room temperature below 22 °C because chlorpyrifos hydrolyzes at higher free-water activity. Gelatin cross-linking from residual aldehydes in the API is monitored by a two-tier dissolution test at pH 1.2 and pH 6.8 according to USP <711>. A representative powder blend for size 0 capsules contains 10% w/w API, 45% microcrystalline cellulose, 39% anhydrous lactose, 4% croscarmellose sodium, 1% colloidal silicon dioxide, and 1% magnesium stearate. The API is pre-screened through a 0.5 mm mesh. The target fill weight for size 0 capsules is 250 mg ± 5%, with weight variation by USP <905>. Blend uniformity is validated per ICH Q2(R1) using a reversed-phase HPLC method with UV detection at 230 nm; system precision is not more than 2.0% RSD. Automated dosator filling is preferred over tamping because the low melting point of the active can cause build-up in tamping pins. Shells are flushed with nitrogen before filling when oxygen-sensitive degradation is observed at 40 °C/75% RH stability stress. The finished 50 mg and 100 mg veterinary oral capsules are packaged in HDPE containers with desiccant silica gel. Published data for chlorpyrifos capsule-specific dissolution in gelatin shell configurations is limited; the in-house method is fully validated per ICH Q2(R1).

Tooling Temperature and Binder Selection for Non-Aqueous Granulation of Chlorpyrifos Oral Granules

For chlorpyrifos oral granules, water-based wet granulation is replaced with a non-aqueous binder solution of povidone K30 in anhydrous ethanol at 5% w/w solids. The dry blend contains 10% w/w API, 50% mannitol, 35% microcrystalline cellulose, and 5% povidone K30. The granulating liquid is added at 3% w/w in a high-shear mixer with jacket temperature maintained at 18–20 °C. Wet mass is passed through a 1.25 mm screen. Vacuum drying is conducted at 30 °C and 10 kPa until loss on drying is not more than 0.8% by USP <731>. The low drying temperature is mandatory because the API melts at 41–42 °C and can form agglomerates that alter drug release. Dried granules are sized between 0.8 mm and 1.25 mm using USP <786> sieve analysis; no more than 15% fine powder below 0.8 mm is allowed. Target sachet fill weight is 1.0 g with bulk density 0.45–0.55 g/mL and tapped density 0.60–0.70 g/mL; Carr index is below 20. The single-dose granules are filled into sachets under 25% RH and sealed with aluminum-laminated film. Reconstitution with 20 mL water gives a coarse suspension for immediate oral administration. Aqueous suspension stability is limited to 30 min after reconstitution because pH elevation above 6.8 accelerates conversion to 3,5,6-trichloro-2-pyridinol. Dissolution of the reconstituted suspension is run with USP <711> apparatus 2 at 50 rpm in 900 mL of 0.1 M hydrochloric acid containing 0.5% sodium lauryl sulfate; the Q value is 80% at 30 min. Residual ethanol is controlled per ICH Q3C(R8) Class 3 limit of 5000 ppm. The finished oral granules are intended for veterinary species where national registration exists. Use in food-producing livestock is excluded because of residue carry-over risk in milk and edible tissues.

Oil-based injectable processing of chlorpyrifos pharma grade is performed with ethyl oleate or fractionated coconut oil as the anhydrous vehicle. Karl Fischer moisture is confirmed below 0.05% w/w before API introduction because free water and alkaline impurities hydrolyze the phosphorothioate bond. A 10% w/w stock solution is prepared under nitrogen in a jacketed glass-lined vessel held at 25–30 °C. Prefiltration and fill are conducted in an ISO 14644-1 Class 5 zone with unidirectional airflow velocity at 0.45 m/s. The solution is filtered through a 0.22 µm PVDF membrane into sterile amber Type I glass vials. Nylon filters are not suitable because the lipophilic API can bind to nylon and reduce assay by more than 5% at batch scale. Vehicle sterilization uses dry heat at 180 °C for 2 h. Terminal autoclaving of the final product is not recommended because published thermal degradation data for chlorpyrifos above 121 °C are limited and oxidative degradation may generate des-ethyl chlorpyrifos. The final injectable solution contains 50 mg/mL or 100 mg/mL chlorpyrifos. Sterility is confirmed by USP <71> independent membrane filtration. Bacterial endotoxins are limited to 0.5 EU/mg by USP <85>. Particulate matter meets USP <788> small-volume parenteral limits of not more than 6000 particles per container at 10 µm and 600 particles per container at 25 µm. Visible particulate inspection follows USP <790>. The rubber stopper is a Teflon-coated chlorobutyl type to limit adsorption of the lipophilic drug. The injectable product is labeled strictly for veterinary use in non-food animals where national authority approves. Intramuscular injection volumes above 2 mL per site are not recommended because local tissue irritation and acetylcholinesterase depression may be concentration-dependent. Published pharmacokinetic data for chlorpyrifos oil-based parenteral formulations in companion animals is limited; therefore pharmacokinetic bridge studies are required before target species use.

Oral emulsion manufacture of chlorpyrifos pharma grade is done with medium-chain triglycerides, soybean lecithin, and anhydrous glycerol. The internal phase is prepared by dissolving API in triglycerides at 35 °C. The aqueous phase contains sorbitol 20% w/w and polysorbate 80 2% w/w in purified water adjusted to pH 5.0 with citric acid. Both phases are mixed using a high-shear rotor-stator homogenizer at 10,000 rpm for 15 min under vacuum. If droplet size D90 remains above 2.0 µm, a high-pressure homogenizer is used at 500 bar for 3 passes. Droplet size is measured by laser diffraction per ISO 13320:2020; the D90 is controlled below 2.0 µm for oral emulsions to reduce creaming. The final emulsion contains 20 mg/mL chlorpyrifos. The pH is maintained below 6.5 throughout shelf life because hydrolysis half-life shortens from 35 days at pH 7.0 to 1.2 days at pH 9.0. The product is filled into amber PET bottles with child-resistant closures. Analytical assay uses reversed-phase HPLC with UV detection at 230 nm; the method is validated per ICH Q2(R1) for linearity, precision, and forced-degradation specificity. The oral emulsion is intended only for non-food veterinary species. Published stability data for chlorpyrifos oral emulsions under WHO accelerated storage conditions is limited; therefore a bracketed stability protocol per ICH Q1A(R2) is applied.

When Sterile Dry Powder for Reconstitution Is Specified for Chlorpyrifos

If a lyophilized or spray-dried sterile presentation is required, the API is first complexed with hydroxypropyl-β-cyclodextrin at a 1:2 molar ratio in a 50% ethanol-water solvent system. The solvent is removed by lyophilization at -30 °C shelf temperature and 0.1 mbar chamber pressure for 48 h. The resulting cake is amorphous by powder X-ray diffraction and yields a reconstituted suspension with a D90 below 10 µm when shaken with 10 mL sterile water. Karl Fischer moisture of the final cake is not more than 1.0% by USP <921>. Residual ethanol is controlled below 5000 ppm per ICH Q3C(R8) Class 3. Each vial contains 50 mg chlorpyrifos equivalent. Sterility is verified by USP <71>. Particulate matter is assessed after reconstitution using USP <788>. The reconstituted product must be administered within 2 h because free drug in contact with water at pH above 6.0 begins to hydrolyze. The cyclodextrin complex reduces but does not eliminate aqueous hydrolysis. Process scalability is limited by cryogenic capacity and residual solvent removal; published data for chlorpyrifos-cyclodextrin lyophilization at production scale is limited. This presentation is not interchangeable with the oil-based injection because pharmacokinetic release of the lipophilic active from the cyclodextrin cavity is faster and may lead to transient acetylcholinesterase depression if dose inputs are duplicated.

Chlorpyrifos pharma grade as an analytical reference standard is sub-divided under 25% RH into 100 mg amber vials with Teflon septa. Mass balance purity assignment is performed by subtracting headspace gas chromatography residual solvents per USP <467>, Karl Fischer moisture per USP <921>, and sulfated ash per USP <281>. Chromatographic purity is determined by reversed-phase HPLC with UV detection at 230 nm; any single unknown impurity is limited to not more than 0.5% and total impurities to not more than 1.0%. The reference material is used to validate assay and related substances methods for tablet, capsule, granule, injection, and oral emulsion batches under ICH Q2(R1). Its use is not for formulation of finished dosage forms. The vialed standard carries a certificate of analysis with assigned purity, expiration, and storage conditions at 2–8 °C in a desiccated enclosure.